🔗 Share this article

As the United States continues making unprecedented adjustments to its vaccine schedules, one figure has emerged in a surprising turn: Dr. Tracy Beth Høeg, a Danish American physician and public health researcher who rose to prominence by expressing skepticism about COVID-19 shots in the pandemic and has zeroed in on potential fatalities following COVID-19 immunization in her brief position at the US Food and Drug Administration (FDA).

Proposed Changes to Childhood Immunization Program

Public health authorities planned to reveal sweeping changes to the childhood vaccination calendar earlier this month, bringing the US with Denmark’s immunization schedule, it is understood – a substantial departure that would place the US out of step with a large portion of the global community with little proof for public health gain. The planned update has been postponed until the new year.

In place of the top vaccines chief, Høeg is listed to present at the gathering. She was just designated acting director of the FDA’s drug evaluation center, the fifth individual to run the division this year.

A Shift at the Regulatory Body

The acting appointment might represent a strengthened alliance between the pharmaceutical and vaccine branches as Dr. Høeg and Dr. Prasad strengthen their influence at the agency – and it suggests a increased emphasis upon rolling back previously authorized immunizations at the FDA.

Dr. Høeg has frequently advocated for discontinuing certain childhood immunization guidelines in the US in order to be more in line with Denmark, a nation with universal health coverage and a population roughly the population of the state of Wisconsin.

In her initial public appearances, she has persisted in emphasizing on immunizations – traditionally the purview of Dr. Prasad, director of the FDA’s Center for Biologics Evaluation and Research (CBER) – rather than drug regulation.

Doubts Over Background

Dr. Høeg has no apparent track record in medication creation, regulation or management, which has been customary for former directors of the Center for Biologics Evaluation and Research. She has served at the FDA as a senior adviser to the FDA chief and CBER since earlier this year.

“It seems she lacks to have any of the qualifications” for running the pharmaceutical oversight division, said a neurologist and psychiatrist. “She lacks experience running a scientific study. She lacks experience in leading a major agency. She has no expertise in pharmaceutical oversight.”

Former heads of CBER would “be deeply familiar with laws and regulations and the underlying principles of drug development”, noted Janet Woodcock. “Frankly, she has not acquired the sort of resume that previous people who led the center have had.”

This division has an vast portfolio at the FDA, Woodcock emphasized.

“The public just focuses on the innovative therapies, but the generic drug division authorizes numerous generic drugs. There is also a biologic copycat branch, OTC medication office and other areas, and all of those need to be looked after,” Dr. Woodcock explained. “The area you don’t keep your eye on, that’s the thing that I always told people is going to bite you.”

Additionally, a major administrative aspect to the role, which oversees more than 5,000 employees. “It’s a massive administrative position, if you do it right,” Woodcock said.

Response and Disputed Policies

When asked about questions about Dr. Høeg's qualifications and whether this assignment represents increased cooperation among FDA leaders on immunizations, a spokesperson stated that the “questions rely on flawed presumptions”.

“Her experience aligns with the duties of her job,” the representative said, citing the months Høeg spent advising the agency head on “drug safety and regulatory science, including predictive safety algorithms and shot safety tracking”.

As acting director, Høeg inherits the commissioner’s controversial expedited review system, a disputed one-day therapy clearance system that allegedly worried her preceding directors. “How are these drugs being selected for this expedited pathway? Who is making the choices?” Howard said. “There is a lot of lack of transparency occurring at the regulatory body right now.”

Broadly speaking, he remarked, “the FDA seems to be moving towards less stringent regulations of pharmaceuticals, except for shots.”

Established Past Work on Immunizations

Concerning vaccines, Dr. Høeg has a more documented, if problematic, past, some experts said. She authored a analysis using unverified public submissions to estimate the rate of heart inflammation after COVID-19 immunization. She advised the Florida surgeon general Joseph Ladapo, who allegedly have changed statistics to indicate Covid vaccinations are more dangerous than they are.

Included in her “wish list” for the new government encompassed revising guidelines for novel immunizations and discontinuing “non-essential” immunizations, she said post-election on a online show. At the FDA, Dr. Høeg has according to sources floated the idea of barring young men from obtaining COVID-19 vaccines.

“She’s an all-around dogmatist who begins with her conclusions and works backwards to fit the evidence in a highly disingenuous, untruthful fashion,” Dr. Howard said.

Consolidating Power and a “Campaign of Retribution”

Dr. Høeg aligned with other skeptics, {like|